FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Andrew Krivoshik

Research Profile

Chemicals & Drugs

Concepts & Ideas

Disorders

Procedures

Administration, Oral

Co-author Network

Publications

TOP 3
Charles Rudin; Geoffrey I Shapiro; Philip D Bonomi; Todd A Busman; D Ross Camidge; Arunava Chakravartty; Quincy Chu; Brenda J Chyla; Caroline Dive; Barry L Dowell; Edward B Garon; Giuseppe Giaccone; CHRISTINE HANN; Rod A Humerickhouse; Divis Khaira; Andrew Krivoshik; M Mabry; Evelyn M McKeegan; Cathy E Nolan; Suresh S Ramalingam; Malcolm R Ranson; Moacyr Ribeiro de Oliveira; Niki Rudersdorf; Leena Gandhi
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
M Silver; J Bauch; E Beck; K Hahn; E Hershey; M Jankowski; Andrew Krivoshik; E McKeegan; J Philibert; B Phillips; Anthony Rusk; C Khanna
Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma.
Andrew W Roberts; John F Seymour; William G Wierda; Hao Xiong; Seong Lin Khaw; Thomas J Kipps; Andrew Krivoshik; Evelyn M McKeegan; Jennifer R Brown; Todd A Busman; Dennis A Carney; Yue Cui; Sari H Enschede; Simon Z He; David C S Huang; Rod A Humerickhouse
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Andrew Krivoshik (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Charles Rudin; Geoffrey I Shapiro; Philip D Bonomi; Todd A Busman; D Ross Camidge; Arunava Chakravartty; Quincy Chu; Brenda J Chyla; Caroline Dive; Barry L Dowell; Edward B Garon; Giuseppe Giaccone; CHRISTINE HANN; Rod A Humerickhouse; Divis Khaira; Andrew Krivoshik; M Mabry; Evelyn M McKeegan; Cathy E Nolan; Suresh S Ramalingam; Malcolm R Ranson; Moacyr Ribeiro de Oliveira; Niki Rudersdorf; Leena Gandhi
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(11):3163-9.
2012: M Silver; J Bauch; E Beck; K Hahn; E Hershey; M Jankowski; Andrew Krivoshik; E McKeegan; J Philibert; B Phillips; Anthony Rusk; C Khanna
Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma.
Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 2012;26(2):349-54.
2012: Andrew W Roberts; John F Seymour; William G Wierda; Hao Xiong; Seong Lin Khaw; Thomas J Kipps; Andrew Krivoshik; Evelyn M McKeegan; Jennifer R Brown; Todd A Busman; Dennis A Carney; Yue Cui; Sari H Enschede; Simon Z He; David C S Huang; Rod A Humerickhouse
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(5):488-96.
2011: Charles Rudin; Ann Mauer; Martin Smakal; Rosalyn A Juergens; Stanislav Spelda; Michael Wertheim; Andrew Coates; Evelyn McKeegan; Peter Ansell; Xiangdong Zhou; Jane Qian; Rajendra Pradhan; Barry Dowell; Andrew Krivoshik; Gary Gordon
Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(8):1075-82.
2011: Leena Gandhi; D Ross Camidge; Moacyr Ribeiro de Oliveira; Philip Bonomi; David R Gandara; Divis Khaira; CHRISTINE HANN; Evelyn M McKeegan; Elizabeth Litvinovich; Philip M Hemken; Caroline Dive; Sari H Enschede; Cathy Nolan; Yi-Lin Chiu; Todd Busman; Hao Xiong; Andrew Krivoshik; Rod Humerickhouse; Geoffrey I Shapiro; Charles Rudin
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(7):909-16.
2010: Wyndham H Wilson; Owen A O'Connor; Myron S Czuczman; Ann S LaCasce; John Gerecitano; John P Leonard; Anil Tulpule; Kieron Dunleavy; Hao Xiong; Yi-Lin Chiu; Yue Cui; Todd Busman; Steven W Elmore; Saul H Rosenberg; Andrew Krivoshik; Sari H Enschede; Rod A Humerickhouse
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
The lancet oncology 2010;11(12):1149-59.
2010: Elizabeth Fox; John M Maris; Susan Cohn; Wendy Goodspeed; Anne Goodwin; Marie Kromplewski; Diane Medina; Hao Xiong; Andrew Krivoshik; BRIGITTE WIDEMANN; Peter Charles Adamson; FRANK BALIS
Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors.
Cancer chemotherapy and pharmacology 2010;66(4):737-43.
2010: Holly J Meany; Dan L Sackett; John M Maris; Yvona Ward; Andrew Krivoshik; Susan Cohn; Seth M Steinberg; FRANK BALIS; Elizabeth Fox
Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro.
Pediatric blood & cancer 2010;54(1):47-54.
2008: Elizabeth Fox; John M Maris; BRIGITTE WIDEMANN; Wendy Goodspeed; Anne Goodwin; Marie Kromplewski; Molly E Fouts; Diane Medina; Susan Cohn; Andrew Krivoshik; Anne Hagey; Peter Charles Adamson; FRANK BALIS
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(4):1111-5.
2006: Elizabeth Fox; John M Maris; BRIGITTE WIDEMANN; Kysa Meek; Anne Goodwin; Wendy Goodspeed; Marie Kromplewski; Molly E Fouts; Diane Medina; Steve Y Cho; Susan Cohn; Andrew Krivoshik; Anne Hagey; Peter Charles Adamson; FRANK BALIS
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(16):4882-7.
2004: B Z Morgenstern; Andrew Krivoshik; V Rodriguez; Peter M Anderson
Wilms' tumor and neuroblastoma.
Acta paediatrica (Oslo, Norway : 1992). Supplement 2004;93(445):78-84; discussion 84-5.
2000: Andrew Krivoshik; L Barr
Force relaxes before the fall of cytosolic calcium in the photomechanical response of rat sphincter pupillae.
American journal of physiology. Cell physiology 2000;279(1):C274-80.